文献速递脑血管病外科

脑动静脉畸形药物治疗进展综述

An Update on Medications for Brain Arteriovenous Malformations.
PubMed 文献 · Neurosurgery · 2020-01-01

本综述总结了脑动静脉畸形(bAVM)药物治疗的研发现状,涵盖贝伐珠单抗、沙利度胺/来那度胺和多西环素等靶向药物,分别针对血管内皮生长因子通路、血脑屏障损害和基质金属蛋白酶过表达,部分已进入人体临床试验。

要点

  • 贝伐珠单抗靶向VEGF驱动血管生成通路。
  • 沙利度胺或来那度胺靶向血脑屏障损害。
  • 多西环素靶向基质金属蛋白酶过表达。

核心结论

  • 多种靶向bAVM的候选药物正在研发,部分已进入人体临床试验,未来可能拓展治疗选择。

研究设计与样本

  • 综述性文章,总结bAVM药物治疗的研发现状与未来应用方向。

主要发现

  • 体外研究加深了对bAVM形成、生长和破裂的理解,并推动治疗靶点开发。
  • 贝伐珠单抗靶向血管内皮生长因子驱动的血管生成通路。
  • 沙利度胺或来那度胺靶向血脑屏障损害。
  • 多西环素靶向基质金属蛋白酶过表达。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite a variety of treatment options for brain arteriovenous malformations (bAVMs), many lesions remain challenging to treat and present significant ongoing risk for hemorrhage. In Vitro investigations have recently led to a greater understanding of the formation, growth, and rupture of bAVMs. This has, in turn, led to the development of therapeutic targets for medications for bAVMs, some of which have begun testing in clinical trials in humans. These include bevacizumab, targeting the vascular endothelial growth factor driven angiogenic pathway; thalidomide or lenalidomide, targeting blood-brain barrier impairment; and doxycycline, targeting matrix metalloproteinase overexpression. A variety of other medications appear promising but either requires adaptation from other disease states or development from early bench studies into the clinical realm. This review aims to provide an overview of the current state of development of medications targeting bAVMs and to highlight their likely applications in the future.

来源:Neurosurgery,查看原文。版权归原作者所有。

引用

  1. Raper DMS, Winkler EA, Rutledge WC, et al. An Update on Medications for Brain Arteriovenous Malformations. Neurosurgery. 2020. PMID: 32433738. doi:10.1093/neuros/nyaa192

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。